Furthermore, prePMF patients had a significantly elevated incidence of SVT than ET patients, and prePMF patients with JAK2-V617F had significantly inferior OS and TFS than prePMF patients with CALR mutations [73]. The gene discussed is JAK2; the disease is essential thrombocythemia.